Get the Stockscreener App
6.92
1.32%
0.09
After Hours:
6.90
-0.02
-0.29%
Cvrx Inc stock is traded at $6.92, with a volume of 361.36K.
It is up +1.32% in the last 24 hours and down -3.28% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$6.83
Open:
$6.92
24h Volume:
361.36K
Relative Volume:
1.18
Market Cap:
$182.08M
Revenue:
$56.65M
Net Income/Loss:
$-53.31M
P/E Ratio:
-3.3852
EPS:
-2.0442
Net Cash Flow:
$-40.75M
1W Performance:
-11.23%
1M Performance:
-3.28%
6M Performance:
-29.67%
1Y Performance:
+45.07%
1-Day Range:
$6.75
$7.23
1-Week Range:
$6.69
$7.92
52-Week Range:
$4.2993
$11.30
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
6.92 | 179.71M | 56.65M | -53.31M | -40.75M | -2.0442 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
CVRx Q1 Earnings Call Highlights - sharewise.com
CVRx Earnings Call Highlights Growth Amid Ongoing Losses - TipRanks
CVRX: Q1 2026 delivered strong revenue growth, margin expansion, and strategic progress in U.S. heart failure therapy - TradingView
CVRX: Q1 2026 revenue grew 20% with strong U.S. performance and improved gross margin - TradingView
CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates - Yahoo! Finance Canada
Earnings call transcript: CVRx beats Q1 2026 forecasts, stock rises By Investing.com - Investing.com Canada
Earnings call transcript: CVRx beats Q1 2026 forecasts, stock rises - Investing.com
CVRx revenue rises 20 percent in first quarter as U.S. operations expand - Traders Union
CVRX Inc (NASDAQ:CVRX) Q1 2026 Earnings Meet Revenue Estimates, Loss Slightly Narrower Than Expected - ChartMill
CVRX ($CVRX) Releases Q1 2026 Earnings - Quiver Quantitative
CVRx: Q1 Earnings Snapshot - marketscreener.com
Medical device company CVRx, Inc. has released its performance guidance for fiscal year 2026. - Bitget
CVRx (CVRX) Q1 2026 Earnings Call Transcript - AOL.com
CVRx Reports First Quarter 2026 Financial and Operating Results - The Manila Times
CVRX: Q1 2026 revenue rose 20% year-over-year, with strong U.S. growth and improved gross margin - TradingView
CVRx's Q1 revenue rises 20%, beats expectations - TradingView
CVRx reports Q1 2026 revenue $14.8M, gross margin 87%, net loss $13.1M - TradingView
CVRx (NASDAQ: CVRX) grows Q1 2026 revenue 20% but remains loss-making - Stock Titan
CVRx heart device trial could expand Barostim patient pool threefold - Stock Titan
CVRx Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Earnings Preview: CVRx Inc to Report Financial Results Post-market on May 11 - 富途牛牛
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating - 富途牛牛
Lake Street Initiates CVRx Inc(CVRX.US) With Buy Rating, Announces Target Price $14 - 富途牛牛
CVRx enrolls first patient in 2,500-patient heart failure trial By Investing.com - Investing.com South Africa
CVRx enrolls first patient in 2,500-patient heart failure trial - Investing.com
CVRx enrolls first patient in study of Barostim therapy for heart failure - MassDevice
CVRx launches landmark BENEFIT-HF trial for cardiac device research - Traders Union
A 2,500-patient heart failure study begins with device access at stake - Stock Titan
CVRx enrolls first patient in BENEFIT-HF trial to expand Barostim heart failure therapy use - Pluang
CVRx reports Barostim therapy boosts quality of life for heart failure patients - Traders Union
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Discipline and Rules-Based Execution in CVRX Response - Stock Traders Daily
Methodist University Hospital completes first Barostim implant with CVRx collaboration - Traders Union
Cantor Fitzgerald Maintains CVRx (CVRX) Overweight Recommendation - MSN
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026 - GlobeNewswire
CVRx, Inc. (NASDAQ:CVRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
CVRx promotes Barostim therapy as new option for heart failure patients at ISHLT2026 - Traders Union
CVRx reports preliminary 2025 results, issues 2026 guidance - MSN
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
CVRx nominates Michael Dale to board of directors By Investing.com - Investing.com India
CVRx nominates Michael Dale to board of directors - Investing.com
Lawnwood Medical Center achieves milestone with 15th Barostim therapy, CVRx confirms - Traders Union
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors - marketscreener.com
Former Abbott structural heart leader Michael Dale lands CVRx board nomination - Stock Titan
CVRx (CVRX) details 2026 virtual meeting, board nominees and pay - Stock Titan
Behavioral Patterns of CVRX and Institutional Flows - Stock Traders Daily
CVRX Should I Buy - Intellectia AI
CVRx unveils Barostim session on neurohormonal targeting at ISHLT2026 - Traders Union
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
CVRX Maintained by Canaccord Genuity -- Price Target Steady at $10 - GuruFocus
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):